N-(benzyloxy)biphenyl-4-sulfonamide | 1061742-67-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(benzyloxy)biphenyl-4-sulfonamide
• 英文别名: Biphenyl-4-sulfonic acid benzyloxy-amide；4-phenyl-N-phenylmethoxybenzenesulfonamide
• CAS: 1061742-67-3
• 化学式: C₁₉H₁₇NO₃S
• 分子量: 339.415
• InChiKey: FIHWWHUXXBHATC-UHFFFAOYSA-N

物化性质

• 熔点：
  130-132 °C
• 沸点：
  504.1±53.0 °C(Predicted)
• 密度：
  1.246±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  63.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-(benzyloxy)biphenyl-4-sulfonamide 在 偶氮二甲酸二异丙酯 、 三苯基膦 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 10.0h， 生成 (R)-2-(N-(benzyloxy)-[1,1'-biphenyl]-4-sulfonamido)-4-(((benzyloxy)carbonyl)amino)butanoic acid
  参考文献：
  名称：

  Diagnostic agents selective against metalloproteases

  摘要：

  该发明涉及具有亲和力针对金属蛋白酶MMP的芳基磺胺基化合物，其具有如下式(I)中所示的结构，其中R、R1、R2、R3、G和n具有规范中报告的含义，适当地标记有诊断成像团或甚至放射治疗团。该发明还涉及它们的制备方法，包括它们的药物组合物和它们作为诊断成像剂或放射治疗剂的用途。

  公开号：

  US09480758B2
• 作为产物：
  描述：

  对联苯磺酰氯 、 苄氧基胺盐酸盐 在 N-甲基吗啉 作用下， 以 四氢呋喃 为溶剂， 反应 0.5h， 以85%的产率得到N-(benzyloxy)biphenyl-4-sulfonamide
  参考文献：
  名称：

  Compounds having aryl-sulphonamidic structure useful as metalloproteases inhibitors

  摘要：

  本发明涉及具有对金属蛋白酶MMP具有抑制活性的芳基磺胺基化合物，其具有以下式（I）其中R、R1、R2、R3、R4、R5、n和m具有规范中报告的含义；本发明还涉及它们的制备方法，包括它们的制药组合物以及它们作为治疗剂的用途，特别是在治疗退行性疾病方面。

  公开号：

  EP1972617A1

文献信息

• ARYL-SULPHONAMIDIC DIMERS AS METALLOPROTEASES INHIBITORS
  申请人：Bracco Imaging S.p.A

  公开号：EP2149568A1

  公开（公告）日：2010-02-03

  The invention relates to dimeric aryl-sulphonamido compounds endowed with inhibitory activity against metalloproteases MMP, having formula (I) below          (M)-L-(M')     (I) wherein M and M', the same or different from each other, represent the residues of the mctalloprotcascs inhibitors of formula (II) wherein R, R1, R2, R3, G and n have the meanings reported in the specification; the invention also refers to the process for their preparation, to pharmaceutical compositions comprising them and to their use as therapeutic agents, particularly in the treatment of degenerative disorders.

  该发明涉及具有对金属蛋白酶MMP具有抑制活性的二聚芳基磺胺基化合物，其具有以下式(I)：(M)-L-(M')，其中M和M'，相同或不同，代表具有以下式(II)金属蛋白酶抑制剂的残基，其中R、R1、R2、R3、G和n在说明书中有所述；该发明还涉及其制备方法，包括它们的药物组合物以及它们作为治疗剂的用途，特别是在治疗退行性疾病方面。
• Compounds having aryl-sulphonamidic structure useful as metalloproteases inhibitors
  申请人：Bracco S.P.A.

  公开号：EP1972617A1

  公开（公告）日：2008-09-24

  The invention relates to aryl-sulphonamido compounds endowed with inhibitory activity against metallo proteases MMP, having formula (I) below wherein R, R1, R2, R3, R4, R5, n and m have the meanings reported in the specification; the invention also refers to the process for their preparation, to pharmaceutical compositions comprising them and to their use as therapeutic agents, particularly in the treatment of degenerative disorders.

  本发明涉及具有对金属蛋白酶MMP具有抑制活性的芳基磺胺基化合物，其具有以下式（I）其中R、R1、R2、R3、R4、R5、n和m具有规范中报告的含义；本发明还涉及它们的制备方法，包括它们的制药组合物以及它们作为治疗剂的用途，特别是在治疗退行性疾病方面。
• Potent Arylsulfonamide Inhibitors of Tumor Necrosis Factor-α Converting Enzyme Able to Reduce Activated Leukocyte Cell Adhesion Molecule Shedding in Cancer Cell Models
  作者：Elisa Nuti、Francesca Casalini、Stanislava I. Avramova、Salvatore Santamaria、Marina Fabbi、Silvano Ferrini、Luciana Marinelli、Valeria La Pietra、Vittorio Limongelli、Ettore Novellino、Giovanni Cercignani、Elisabetta Orlandini、Susanna Nencetti、Armando Rossello

  DOI：10.1021/jm901868z

  日期：2010.3.25

  useful target in anticancer therapy. Herein, we report the synthesis and biological evaluation of new ADAM-17 inhibitors containing an arylsulfonamidic scaffold. Among the new potential inhibitors, two very promising compounds 17 and 18 were discovered, with a nanomolar activity for ADAM-17 isolated enzyme. These compounds proved to be also the most potent in inhibiting soluble ALCAM release in cancer

  活化的白细胞粘附分子（ALCAM）在肿瘤生物学和进展中起着重要作用。我们以前的研究表明，ALCAM在上皮性卵巢癌（EOC）细胞表面表达，并通过ADAM-17介导的脱落以可溶形式释放。此过程与EOC细胞的运动性和侵袭性有关，ADAM-17的非特异性抑制剂会降低EOC的细胞运动性和侵袭性。因此，ADAM-17可能代表抗癌治疗的新靶标。在此，我们报告了含有芳基磺酰胺基支架的新型ADAM-17抑制剂的合成和生物学评估。在新的潜在抑制剂中，两种非常有前途的化合物17和18被发现具有ADAM-17分离酶的纳摩尔活性。这些化合物被证明也是抑制癌细胞中可溶性ALCAM释放的最有效剂，对A2774和SKOV3细胞系表现出纳摩尔活性。
• [EN] ARYL-SULPHONAMIDIC DIMERS AS METALLOPROTEASES INHIBITORS<br/>[FR] DIMÈRES ARYL-SULFONAMIDIQUES EN TANT QU'INHIBITEURS DE MÉTALLOPROTÉASES
  申请人：BRACCO IMAGING SPA

  公开号：WO2010010080A1

  公开（公告）日：2010-01-28

  The invention relates to dimeric aryl-sulphonamido compounds endowed with inhibitory activity against metalloproteases MMP, having formula (I) below (M)-L-(M') (I), wherein M and M', the same or different from each other, represent the residues of the metalloproteases inhibitors of formula (II), wherein R, R1, R2, R3, G and n have the meanings reported in the specification; the invention also refers to the process for their preparation, to pharmaceutical compositions comprising them and to their use as therapeutic agents, particularly in the treatment of degenerative disorders.
• Diagnostic agents selective against metalloproteases
  申请人：Rossello Armando

  公开号：US09480758B2

  公开（公告）日：2016-11-01

  The invention relates to aryl-sulphonamido compounds endowed with affinity against metallo proteases MMP, having formula (I) below wherein R, R1, R2, R3, G and n have the meanings reported in the specification, properly labelled with diagnostic imaging moieties or even radiotherapeutic moieties. The invention also refers to the process for their preparation, to pharmaceutical compositions comprising them and to their use as diagnostic imaging agents or radiotherapeutic agents.

  该发明涉及具有亲和力针对金属蛋白酶MMP的芳基磺胺基化合物，其具有如下式(I)中所示的结构，其中R、R1、R2、R3、G和n具有规范中报告的含义，适当地标记有诊断成像团或甚至放射治疗团。该发明还涉及它们的制备方法，包括它们的药物组合物和它们作为诊断成像剂或放射治疗剂的用途。